Michael Kramer

Michael Kramer

Michael Kramer is the Founder of Mott Capital Management. His unique investment philosophy centers on seeking investment opportunities that are influenced by everyday life activities, and by observing new trends and products that are popular or are trending towards popularity. Additionally, he devotes a significant part of his research to global macroeconomics and central bank policies impacting financial markets.

Kramer runs the Mott Capital Management actively managed long-only Thematic Growth Portfolio, which holds these stocks: AAPL, ACAD, ALKS, CELG, DEO, DIS, GOOGL, MA, MO, NFLX, NXPI, RTN, SWKS TSLA, UL, V, VOD and VZ.

Kramer began his career in high-risk trading environments, trading both US and international equities. His trading skills coupled with his comprehensive, financial analysis of public companies, have given him a unique perspective on investing, which stands out from analysts who simply look at top-line numbers. In addition to fundamental analysis, Kramer also incorporates technical and options market analysis into his research.

Kramer is a fundamental writer for Investopedia.com, analyzing stocks and market news that is helpful for everyday investors to make short and long-term investment decisions.

  1. Stocks

    Teva Plummets in Early Trading (Teva)

    Pantent claims invalidated by a US District Court is another blow in Teva's effort to get back on the revenue growth track.
  2. Stocks

    Eli Lilly & Co. Part of Lawsuit Over Insulin (LLY)

    According to the New York Times, Eli Lilly & Co. was named in a federal lawsuit over insulin pricing.
  3. Stocks

    The Best Value In the Semiconductor Space (AVGO, NVDA)

    Uncovering deals in the Semiconductor space is easy with fundamental analysis.
  4. Stocks

    AMC: Preliminary Numbers Ahead of the Street (AMC)

    The company's preliminary results look promising but where is the growth really coming from?
  5. Stocks

    BTIG Negative on J&J/Actelion Deal (JNJ)

    The acquisition of Actelion will add little to the bottom line of J&J, according to reports.
  6. Stocks

    JP Morgan Reinstates Lions Gate (LGF.A, LGF.B)

    JP Morgan reinstated coverage of Lions Gate with a rating of "outperform" and a $34 price target.
  7. Stocks

    RBC: Autos to Gain Net Benefit From Trump (GM, F)

    President Trump has talked "bigly" about helping the automakers. What will corporate tax cuts really mean?
  8. Stocks

    GM To Move Jobs From Canada To Mexico (GM)

    More debate over NAFTA ensues as GM plans to moves jobs to Mexico.
  9. Stocks

    PFE Gets Positive Review on Arthritis Drug (PFE)

    Pfizer received a positive opinion from CHMP today for XELJANZ - a rheumatoid arthritis drug. Will it also spur growth?
  10. Stocks

    Is Teva Seeing a Dead Cat Bounce? Probably (TEVA)

    Teva shares are up about 2% after announcing an antitrust settlement.
  11. Stocks

    Pandora Falls on OTR Global Report (P)

    OTR Global concerned with slower ad spending at Pandora.
  12. Stocks

    Pfizer Sees Positive Results in New Vaccine (PFE)

    PFE reported positive Phase 2 results for its vaccine to prevent Clostridium difficile (C. difficile).
  13. Stocks

    Ford Earnings Disappoint, But Revenue Beats (F)

    Investors were left with little in the tank after Ford's Q4 earnings release this morning.
  14. Stocks

    J&J Buying Actelion for $30 Billion Cash (JNJ)

    J&J paid roughly 15 times revenue for Actelion. R&D business to be spun off as separate entity.
  15. Stocks

    The On-Demand Generation Will Forever Change Media (NFLX, AMZN)

    The On-Demand Generation is radically altering the media landscape in the United States and around the world.